• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

Fat Tail Daily

Investment Ideas From the Edge of the Bell Curve

  • Menu
    • Commodities
      • Resources and Mining
      • Copper
      • Gold
      • Iron Ore
      • Lithium
      • Silver
      • Graphite
      • Rare Earths
    • Technology
      • AI
      • Bitcoin
      • Cryptocurrency
      • Energy
      • Financial Technology
      • Bio Technology
    • Market Analysis
      • Latest ASX News
      • Dividend Shares
      • ETFs
      • Stocks and Bonds
    • Macro
      • Australian Economy
      • Central Banks
      • World Markets
    • Small Caps
    • More
      • Investment Guides
      • Premium Research
      • Editors
      • About
      • Contact Us
  • Latest
  • Fat Tail Series
  • About Us
Technology Bio Tech

Mesoblast Share Price Up on Encouraging COVID-19 Trails (ASX:MSB)

Like 0

By Carl Wittkopp, Wednesday, 11 November 2020

At time of writing, the Mesoblast Ltd [ASX:MSB] share price is up 4.47%, trading at $3.27. The MSB share price moved higher after announcing positive outcomes in relation to Remestemcel-L phase three trials...

At time of writing, the Mesoblast Ltd [ASX:MSB] share price is up 4.47%, trading at $3.27.

The MSB share price moved higher after announcing positive outcomes in relation to Remestemcel-L phase three trials for COVID-19 acute respiratory distress syndrome (ARDS).

ASX MSB Share Price Chart

Source: Optuma

MSB share price gets lift from stage three trials

Biotechnology companies like Mesoblast are working rapidly on COVID-19 solutions.

Globally, currently there are 51.3 million cases, 33.4 million recovered, and sadly, 1.27 million deaths.

MSB’s drug, Remestemcel-L, is designed for moderate to severe acute respiratory distress syndrome (ARDS) due to COVID-19 infection.

Here’s the punchline from today’s announcement:

‘The company recently announced that the randomized controlled Phase 3 trial of Remestemcel-L in patients with moderate to severe acute respiratory distress syndrome (ARDS) due to COVID-19 infection had received a recommendation to continue from the independent Data Safety Monitoring Board (DSMB) following completion of the trial’s second interim analysis.’

These trails were performed on 135 people.

Outlook for Mesoblast share price may hinge on competition

Taking a quick look at the chart for MSB shares, you can see some immense spikes as well as sharp falls:

Mesoblast Share Price Chart

Source: Optuma

From where the MSB share price sits at time of writing, if it falls away further, then the level of $3.00 may be enough to halt the fall, proving strong in the past.

Should it turn to the upside, then the levels of $3.38 and $4.45 may become the focus in the future.

I think the outlook for the MSB share price may hinge on the competing solutions that come to market.

For example, if the Pfizer and BioNTech vaccine is as effective as they hope, the need for therapies like MSB’s product may diminish.

If the virus can’t replicate in the first place, it may not matter if MSB’s product is effective.

This is a key risk.

If you are looking for other companies that may benefit from post-lockdown conditions, you can find that here.

Two companies covered in this free report do safety technology.

Regards,

Carl Wittkopp,
For Money Morning

All advice is general advice and has not taken into account your personal circumstances.

Please seek independent financial advice regarding your own situation, or if in doubt about the suitability of an investment.

Comments

Subscribe
Notify of
guest
guest
0 Comments
Inline Feedbacks
View all comments
Carl Wittkopp

Carl’s Premium Subscriptions

Publication logo
Fat Tail Investment Research

Latest Articles

  • OpenAI and Microsoft Divorce?: Why this could be good for you
    By Charlie Ormond

    While breakups are rarely pretty, this one might actually benefit investors willing to look beyond the drama.

  • Three Lithium Stocks in the Buy Zone
    By Murray Dawes

    Lithium stocks jumped this week, so Murray and Callum discuss whether this could be the beginning of the second boom in lithium stocks. They also discuss a fund manager that is recovering and looking cheap

  • Every Australian Investor Has a Stake in Mining
    By James Cooper

    With its deep pool of retirement capital, Australia is on track to become the world’s primary destination for resource markets.

Primary Sidebar

Latest Articles

  • OpenAI and Microsoft Divorce?: Why this could be good for you
  • Three Lithium Stocks in the Buy Zone
  • Every Australian Investor Has a Stake in Mining
  • The next wave of AI winners
  • Could the US People Repudiate the National Debt?

Footer

Fat Tail Daily Logo
YouTube
Facebook
x (formally twitter)
LinkedIn

About

Investment ideas from the edge of the bell curve.

Go beyond conventional investing strategies with unique ideas and actionable opportunities. Our expert editors deliver conviction-led insights to guide your financial journey.

Quick Links

Subscribe

About

FAQ

Terms and Conditions

Financial Services Guide

Privacy Policy

Get in Touch

Contact Us

Email: support@fattail.com.au

Phone: 1300 667 481

All advice is general in nature and has not taken into account your personal circumstances. Please seek independent financial advice regarding your own situation, or if in doubt about the suitability of an investment.

The value of any investment and the income derived from it can go down as well as up. Never invest more than you can afford to lose and keep in mind the ultimate risk is that you can lose whatever you’ve invested. While useful for detecting patterns, the past is not a guide to future performance. Some figures contained in our reports are forecasts and may not be a reliable indicator of future results. Any actual or potential gains in these reports may not include taxes, brokerage commissions, or associated fees.

Fat Tail Logo

Fat Tail Daily is brought to you by the team at Fat Tail Investment Research

Copyright © 2025 Fat Tail Daily | ACN: 117 765 009 / ABN: 33 117 765 009 / ASFL: 323 988